Ireland
--:--IST
Priya Life Science Sponsor trial record
Sponsor · clinical trials

Azienda Ospedaliero Universitaria Maggiore della Carita clinical trials

Also registered as Azienda Ospedaliero-Universitaria Maggiore Della Carita
Source: ClinicalTrials.gov, U.S. National Library of Medicine and the EU Clinical Trials Information System (CTIS) — current trials in our Italy and EU (CTIS) registers with Azienda Ospedaliero Universitaria Maggiore della Carita as lead sponsor. Synced 21 Nov 2026
11Current trials
9Recruiting now
1Drug in these trials
2Trial registers
At a glance

Azienda Ospedaliero Universitaria Maggiore della Carita is the lead sponsor of 11 current clinical trials in our Italy and EU (CTIS) registers. 9 are recruiting patients now. The most common phase is Observational. The drugs named most often in its trials are Semaglutide. The most-studied condition is Obesity.

ClinicalTrials.gov trials by status

  • Recruiting990%
  • Active, closed110%

Trials by phase

  • Observational770%
  • Not applicable330%
01

Clinical trials sponsored by Azienda Ospedaliero Universitaria Maggiore della Carita

10 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
Targeting the Hepatic BMP-SMAD Pathway in Leptin Receptor Deficiency (LEPRD)
NCT07833592 · ClinicalTrials.gov ↗ · Leptin Receptor Deficiency Obesity
Observational Recruiting 2026-09 Italy
Phenotyping Patients With Type 2 Diabetes Mellitus and Cancer
NCT06299800 · ClinicalTrials.gov ↗ · Diabetes Mellitus, Type 2, Cancer
Observational Recruiting 2024-02 Italy
Artificial Intelligence-based Platform, Integrating Pathologic, Imaging and Molecular Profiles of Prostate Cancer
NCT06468332 · ClinicalTrials.gov ↗ · Prostate Cancer
Observational Recruiting 2024-10 Italy
Development of Smart Food /Nutraceutical Solutions Dedicated to Cardiometabolic Disorders in Ageing
NCT07817290 · ClinicalTrials.gov ↗ · Prediabetes
Not applicable Recruiting 2025-06 Italy
European Active Surveillance of Renal Cell Carcinoma Study (EASE RCC Study)
NCT06336187 · ClinicalTrials.gov ↗ · Renal Cell Carcinoma
Observational Recruiting 2018-06 Italy
Microparticles Blood Level in Acute Carbon Monoxide Poisoning
NCT05591300 · ClinicalTrials.gov ↗ · Carbon Monoxide Poisoning
Observational Recruiting 2022-11 Italy
The ROTAtional-USE of Interface STUDY
NCT05513508 · ClinicalTrials.gov ↗ · Pressure Ulcer, Noninvasive Positive Pressure Ventilation, Acute Hypercapnic Respiratory Failure
Not applicable Recruiting 2022-12 Italy
Investigating the Link Between Advanced Glycation End Products (AGEs) and Muscle Wasting in Sarcobesity
NCT06438900 · ClinicalTrials.gov ↗ · Sarcopenia, Obesity
Observational Recruiting 2024-06 Italy
Susceptibility to Infectious Diseases in Obesity
NCT05975541 · ClinicalTrials.gov ↗ · Obesity, Type2diabetes, Gut Microbiota
Observational Recruiting 2023-10 Italy
Effects of VLCKD in Metabolic Syndrome
NCT05275608 · ClinicalTrials.gov ↗ · Diabetes Mellitus, Type 2, Non-alcoholic Fatty Liver Disease, Obesity
Not applicable Active, closed 2022-11 Italy

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Azienda Ospedaliero Universitaria Maggiore della Carita in the EU trials register (CTIS)

1 trial

Authorised or ongoing trials in the EU Clinical Trials Information System with Azienda Ospedaliero Universitaria Maggiore della Carita as sponsor. Some are the same study as a ClinicalTrials.gov record above; the two registries share no common ID. Trials with a site in Ireland are listed first.

StudyPhaseStatusCountries
Changes in Coronary Plaque Composition By Semaglutide Use in Diabetic Patients With Acute Coronary Syndrome: A Randomized Optical Coherence Tomography Trial - ARMYDA - 10 study
2025-523977-40-00 · CTIS ↗ · Cardiovascular Diseases
Phase 4 Authorised Italy
03

Drugs in Azienda Ospedaliero Universitaria Maggiore della Carita trials

1 compound

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

04

Conditions in Azienda Ospedaliero Universitaria Maggiore della Carita trials

17 conditions
Obesity3Diabetes Mellitus, Type 22Leptin Receptor Deficiency Obesity1Non-alcoholic Fatty Liver Disease1Metabolic Syndrome1Cancer1Prostate Cancer1Prediabetes1Renal Cell Carcinoma1Carbon Monoxide Poisoning1Pressure Ulcer1Noninvasive Positive Pressure Ventilation1Acute Hypercapnic Respiratory Failure1Sarcopenia1Type2diabetes1Gut Microbiota1Chronic Disease1
05

By trial register

RegisterTrialsRecruiting
Clinical trials in Italy109
EU register (CTIS)1—

A trial with sites in more than one country appears in each of those registers.

06

Other sponsors in Obesity

SponsorTrials
Novo Nordisk66
Eli Lilly and Company46
Pfizer14
Boehringer Ingelheim11
Amgen9
Cairo University9
Assistance Publique - Hôpitaux de Paris8
Istituto Auxologico Italiano7
China-Japan Friendship Hospital6
Kailera5

Sponsors with the most current trials registered for this condition.

07

Questions about Azienda Ospedaliero Universitaria Maggiore della Carita trials

How many clinical trials does Azienda Ospedaliero Universitaria Maggiore della Carita sponsor?

Azienda Ospedaliero Universitaria Maggiore della Carita is the lead sponsor of 10 current trials on ClinicalTrials.gov in our Italy register, and 1 authorised or ongoing trial in the EU register (CTIS), as of the registry sync on 21 November 2026. Completed and withdrawn studies are not counted.

Are Azienda Ospedaliero Universitaria Maggiore della Carita trials recruiting?

Yes. 9 of its 10 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Azienda Ospedaliero Universitaria Maggiore della Carita testing?

Its current trials name 1 drug or biological as interventions. The most frequent are Semaglutide (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 21 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.